Rhumbline Advisers Castle Biosciences Inc Transaction History
Rhumbline Advisers
- $103 Billion
- Q1 2024
A detailed history of Rhumbline Advisers transactions in Castle Biosciences Inc stock. As of the latest transaction made, Rhumbline Advisers holds 38,908 shares of CSTL stock, worth $827,184. This represents 0.0% of its overall portfolio holdings.
Number of Shares
38,908
Previous 37,908
2.64%
Holding current value
$827,184
Previous $818,000
5.26%
% of portfolio
0.0%
Previous 0.0%
Shares
17 transactions
Others Institutions Holding CSTL
# of Institutions
162Shares Held
25.3MCall Options Held
82.2KPut Options Held
150K-
Black Rock Inc. New York, NY2.6MShares$55.2 Million0.0% of portfolio
-
Wasatch Advisors Inc Salt Lake City, UT2.55MShares$54.2 Million0.3% of portfolio
-
Granahan Investment Management, LLC Waltham, MA1.63MShares$34.6 Million1.3% of portfolio
-
Principal Financial Group Inc Des Moines, IA1.53MShares$32.6 Million0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.49MShares$31.8 Million0.0% of portfolio
About CASTLE BIOSCIENCES INC
- Ticker CSTL
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 26,297,000
- Market Cap $559M
- Description
- Castle Biosciences, Inc., a commercial-stage diagnostics company, focuses to provide diagnostic and prognostic testing services for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify the risk of metastasis for patients diagnosed with invasive cutaneous melanoma. The company als...